Boston Scientific Corporation (BSX) : Raveneur Investment Group Lp scooped up 209,381 additional shares in Boston Scientific Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 1,085,173 shares of Boston Scientific Corporation which is valued at $25,924,783.Boston Scientific Corporation makes up approximately 14.30% of Raveneur Investment Group Lp’s portfolio.
Other Hedge Funds, Including , Blackrock Advisors boosted its stake in BSX in the latest quarter, The investment management firm added 2,677,033 additional shares and now holds a total of 16,722,404 shares of Boston Scientific Corporation which is valued at $399,498,232. Boston Scientific Corporation makes up approx 0.42% of Blackrock Advisors’s portfolio. Stephens Inc Ar sold out all of its stake in BSX during the most recent quarter. The investment firm sold 10,683 shares of BSX which is valued $257,888. Boston Family Office added BSX to its portfolio by purchasing 30,875 company shares during the most recent quarter which is valued at $745,323. Boston Scientific Corporation makes up approx 0.09% of Boston Family Office’s portfolio.
Boston Scientific Corporation opened for trading at $24.03 and hit $24.355 on the upside on Monday, eventually ending the session at $24.3, with a gain of 1.38% or 0.33 points. The heightened volatility saw the trading volume jump to 69,32,297 shares. Company has a market cap of $33,066 M.
On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by Wedbush on Jul 29, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $23 .Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .Company shares were Reiterated by The Benchmark Company on Jul 28, 2016 to “Buy”, Firm has raised the Price Target to $ 31 from a previous price target of $25 .
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.